[2] The safety profile of Orforglipron was consistent with existing GLP-1 therapies, with the most common adverse events being mild to moderate gastrointestinal symptoms such as diarrhea, nausea, dyspepsia, and constipation
Medicaid Prime does not cover mental health services, though RMHP works with mental health centers to enhance the integration of physical and mental health services
Studies in cultured hepatocytes and in vivo
however, it is not yet approved for use Boehringer Ingelheim, a biopharmaceutical company headquartered in Ingelheim, Germany, has announced promising results from its Phase 3 SYNCHRONIZE-1 clinical trial testing survodutide
Whilst direct mechanistic links to GLP-1 are still being investigated, the NHS recommends maintaining consistent sleep patterns of 79 hours per night for overall health, including metabolic wellbeing
Here's what you need to know